← back to search

Xiaohui Zhang

Capital Normal University · CN
Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, and Chronic Myeloid Leukemia Treatments.
h-index
64
citations
23,044
works
1,324
NIH funding
primary concept
email

Recent publications

Conditioning dose adjustment in obese adult patients with severe aplastic anemia undergoing haploidentical hematopoietic stem cell transplantation: a propensity score-matched analysis.
2026cited by 0position: contributordoi
Second alternative-donor haploidentical stem cell transplantation enhances survival in patients with myeloid malignancies complicated by posttransplant human leukocyte antigen loss relapse.
2026cited by 0position: contributordoi
Is sex chromosome loss a predictive marker for outcome after sex-mismatched allogeneic hematopoietic stem cell transplantation?
2026cited by 0position: contributordoi
Chronic graft-versus-host disease after haploidentical transplantation in aplastic anemia: clinical characteristics, risk factors, and survival outcomes.
2026cited by 0position: contributordoi
Decoding the molecular drivers of TP53-mutant acute myeloid leukaemia: Clinical implications and prognostic insights.
2026cited by 0position: contributordoi
Endothelial Activation and Stress Index predict GVHD-free, relapse-free survival in adults undergoing haploidentical haematopoietic stem cell transplantation
2026cited by 0position: contributordoi
Impact of concurrent graft-versus-host disease on long-term survival in critically ill patients following allogeneic hematopoietic stem cell transplantation for hematological malignancies
Transplantation and Cellular Therapy 2026cited by 0position: contributordoi
Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Cancer Letters 2025cited by 7position: contributordoi
Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia.
2025cited by 5position: contributordoi
Pre-transplant disease burden rather than age or donor type was associated with survival of hematopoietic cell transplantation for elderly patients with acute myeloid leukemia.
2025cited by 3position: contributordoi
TGF-β1-triggered maladaptive bone marrow endothelium impedes hematopoietic recovery.
2025cited by 2position: contributordoi
Comparison of outcomes between haploidentical and matched related donors for chronic myelomonocytic leukemia: A multicenter real-world study.
2025cited by 2position: contributordoi
Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study.
2025cited by 2position: contributordoi
Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.
2025cited by 2position: contributordoi
The outcomes of second haploidentical donor transplantation for graft failure in patients with severe aplastic anaemia
Annals of Hematology 2025cited by 2position: middledoi
Impact of TP53 alteration on allogeneic hematopoietic cell transplantation outcomes for myelodysplastic syndromes.
2025cited by 1position: contributordoi
Monitoring the KMT2A gene post-chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation.
2025cited by 1position: contributordoi
Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia
Blood 2025cited by 0position: middledoi
The Impact of Blast Percentage on Posttransplant Outcomes of Patients With Myelodysplastic Syndromes: A Retrospective Analysis Within the IPSS-M Framework.
2025cited by 0position: contributordoi
Transplantation Related Mortality Did Not Show Significant Differences in Patients Aged Above 55 Years With Hematological Malignancies Receiving Allogeneic Hematopoietic Stem Cell Transplantation in a Real-World Study.
2025cited by 0position: contributordoi
Incidence, Risk Factors, and Prognosis of Acute Kidney Injury in Elderly Patients With Acute Leukemia Undergoing Haploidentical Hematopoietic Stem Cell Transplantation.
2025cited by 0position: contributordoi
Clinical Characteristics and Outcomes of Influenza-Associated Late-Onset Severe Pneumonia After Allogeneic Hematopoietic Stem Cell Transplantation.
2025cited by 0position: contributordoi
Incidence, Risk Factors, and Impact on Transplant Outcomes of Cytokine Release Syndrome After Infusion of Haploidentical Stem Cells With Anti-Thymocyte Globulin.
2025cited by 0position: contributordoi
Long-term survival in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who relapse after allogeneic hematopoietic stem cell transplantation: a single-center experience.
2025cited by 0position: contributordoi
Correction: Impact of TP53 alteration on allogeneic hematopoietic cell transplantation outcomes for myelodysplastic syndromes.
2025cited by 0position: contributordoi
The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation.
2025cited by 0position: contributordoi
Comparison of allo-SCT versus consolidation chemotherapy as post-remission therapy in acute lymphoblastic leukaemia aged ≥55 years.
2025cited by 0position: contributordoi
Cell softness renders cytotoxic T lymphocytes and T leukemic cells resistant to perforin-mediated killing
Nature Communications 2024cited by 27position: middledoi
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
The Lancet Haematology 2024cited by 27position: middledoi
Cell softness renders cytotoxic T lymphocytes and T leukemic cells resistant to perforin-mediated killing.
2024cited by 25position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 87 papers (2019–2026)Xiao‐Jun Huang · Lanzhou University59 papers (2016–2026)Yu Wang · Affiliated Hospital of Liaoning University of Traditional Chinese Medicine50 papers (2017–2026)Lan-Ping Xu · Peking University48 papers (2020–2026) · 47 papers (2020–2026) · 44 papers (2019–2026)Xiao‐Dong Mo · Peking University35 papers (2019–2026)Ying‐Jun Chang · Peking University18 papers (2016–2026) · 16 papers (2019–2026)Yuqian Sun · Lanzhou University15 papers (2017–2026) · 15 papers (2024–2026)Cheng Yifei · Springer Nature11 papers (2022–2026)Yu Fu · Harbin Medical University8 papers (2012–2018)Jinyu Chi · Harbin Medical University8 papers (2012–2022)Kai‐Yan Liu · South China Agricultural University8 papers (2019–2025)Xiang-Yu Zhao · Elsevier, Inc.8 papers (2019–2025)Xinhua Yin · Harbin Medical University8 papers (2012–2020)Tongying Zhu · Fudan University7 papers (2012–2015)Wenxiu Liu · Harbin Medical University7 papers (2013–2022)Huiping Zhao · University of Illinois Chicago7 papers (2012–2015)